| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/30/2002 | CN1078480C Somatostatin binding peptide-metal chelate conjugates |
| 01/30/2002 | CN1078476C Gastric cancer treating Chinese medicine preparation |
| 01/30/2002 | CN1078474C Snuff for treating mastopathy and its inhalator |
| 01/30/2002 | CN1078470C Anti-cancer medicinal composition and its preparing method |
| 01/29/2002 | US6342765 Imidazole derivatives and their use as farnesyl protein transferase inhibitors |
| 01/29/2002 | US6342602 Bind specifically or selectively to rar-alpha receptors |
| 01/29/2002 | US6342596 Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| 01/29/2002 | US6342584 Antiproliferative, anticarcinogenic, antitumor, antiinflammatory, and antimetastasis agents; diabetes, restenosis, rheumatoid arthritis treatment; genetic engineering |
| 01/29/2002 | US6342521 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides |
| 01/29/2002 | US6342510 Antiinflammatory agents and enzyme inhibitors |
| 01/29/2002 | US6342505 Use of 4-substituted tetrahydropyridines for making medicines acting on TGF-β1 |
| 01/29/2002 | US6342490 Antiproliferation of cells |
| 01/29/2002 | US6342487 Compositions containing at least one farnesyl transferase inhibitor and at least one topoisomerase inhibitor and compositions containing at least one farnesyl transferase inhibitor and at least one taxoid |
| 01/29/2002 | US6342480 Tumor-activated prodrug compounds and treatment |
| 01/29/2002 | US6342392 Isolation of human and murine wild-type int6 gene cdna; cancer diagnosis; gene and immunotherapy; vaccines; gene expression |
| 01/29/2002 | US6342254 Anti-proliferative preparations |
| 01/29/2002 | US6342244 Hydrophilic polymer covalently yet reversibly linked to a amine-containing ligand through a dithiobenzyl linkage; modification of various substrates, such as polypeptides, drugs and liposomes; upon cleavage of the linkage, the ligand |
| 01/29/2002 | US6342234 Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence |
| 01/29/2002 | US6342224 For prophylaxis and therapy of human papilloma induced tumours |
| 01/29/2002 | US6342221 Antibody conjugate compositions for selectively inhibiting VEGF |
| 01/29/2002 | US6342219 As anti-angiogenic and in tumor therapy |
| 01/29/2002 | US6342217 Radiation enhanced gene therapy for tumors expressing a gene for a viral pyrimidine kinase in the presence of a 5′-halogenated pyrimidine |
| 01/29/2002 | US6342216 Therapy of cancer by insect cells containing recombinant baculovirus encoding genes |
| 01/29/2002 | CA2194555C Implanted device containing tumor cells for the treatment of cancer |
| 01/29/2002 | CA2145296C Benzenealkanoic acids for cardiovascular diseases |
| 01/28/2002 | CA2704693A1 Indole derivatives and their use as medicaments |
| 01/28/2002 | CA2704691A1 Indole derivatives and their use as medicaments |
| 01/24/2002 | WO2002006515A2 Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
| 01/24/2002 | WO2002006492A1 A novel human soluble secreted endopeptidase (sep) for the treatment of sexual dysunfction |
| 01/24/2002 | WO2002006486A1 Fused protein with antitumor effect |
| 01/24/2002 | WO2002006483A1 Novel physiologically active peptide and use thereof |
| 01/24/2002 | WO2002006482A1 Receptor protein specifically recognizing bacterial dna |
| 01/24/2002 | WO2002006481A1 Target of anticancer agent |
| 01/24/2002 | WO2002006466A1 Novel g protein-coupled receptor protein and dna thereof |
| 01/24/2002 | WO2002006465A2 7677, a novel human atpase family member and uses therefor |
| 01/24/2002 | WO2002006462A2 Methylated nucleotide regulation of upa gene expression |
| 01/24/2002 | WO2002006453A2 Regulation of human desc1-like serine protease |
| 01/24/2002 | WO2002006347A1 A selectively-expressed epitope on the human cd38 molecule detected by a phage display library-derived human scfv antibody fragment |
| 01/24/2002 | WO2002006340A2 Tetraspan protein and uses thereof |
| 01/24/2002 | WO2002006332A1 A new polypeptide- human fk506 binding protein 13.42 and the polynucleotide encoding it |
| 01/24/2002 | WO2002006317A2 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 01/24/2002 | WO2002006308A2 Methods for promoting dendritic cell proliferation or differentiation |
| 01/24/2002 | WO2002006307A1 Reduced fk228 and use thereof |
| 01/24/2002 | WO2002006300A2 Mutated pf-4, its fragments and mutated fusion peptides, their analogues, corresponding dna, cdna and mrna sequences and their use for inhibiting angiogenesis |
| 01/24/2002 | WO2002006297A1 Novel antisense oligonucleotide derivatives against wilms's tumor gene |
| 01/24/2002 | WO2002006293A1 Matrix metalloproteinase inhibitors |
| 01/24/2002 | WO2002006284A1 Indoloquinazolinones |
| 01/24/2002 | WO2002006282A1 Molecules capable of binding to telomere and the like and method with the use of the same |
| 01/24/2002 | WO2002006271A1 Pyrimidine derivatives |
| 01/24/2002 | WO2002006267A2 Synthesis and biological evaluation of analogs of the antimitotic marine natural product curacin a |
| 01/24/2002 | WO2002006249A1 Method for producing 1-substituted-1,2,3-triazole derivative |
| 01/24/2002 | WO2002006240A1 Substituted 4,9-dihydrocyclopenta[imn] phenanthridine-5-ones, derivatives thereof and their uses |
| 01/24/2002 | WO2002006224A1 Pyrrolidine-2-carboxylic acid hydrazide derivatives for use as metalloprotease inhibitors |
| 01/24/2002 | WO2002006223A1 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| 01/24/2002 | WO2002006222A1 Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme |
| 01/24/2002 | WO2002006215A1 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acid derivates |
| 01/24/2002 | WO2002006213A2 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| 01/24/2002 | WO2002006189A2 Aniline derivatives |
| 01/24/2002 | WO2002005859A2 Radiotherapy |
| 01/24/2002 | WO2002005857A2 Phosphatonin-related gene and methods of use thereof |
| 01/24/2002 | WO2002005852A1 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease |
| 01/24/2002 | WO2002005843A2 Human rrp sequences and methods of use |
| 01/24/2002 | WO2002005830A2 Extracts from crassulacean acid metabolism (cam) mechanism plants and uses thereof |
| 01/24/2002 | WO2002005828A1 Compositions and methods for the treatment of skin damage |
| 01/24/2002 | WO2002005827A2 Use of natural products in cancer treatment |
| 01/24/2002 | WO2002005824A1 USE OF 2α-METHYL-19-NOR-20(S)-1α,25-DIHYDROXYVITAMIN D3 TO INCREASE BONE STRENGTH |
| 01/24/2002 | WO2002005823A2 USE OF 2-METHYLENE-19-NOR-20(S)-1α,25-DIHYDROXYVITAMIN D3 TO INCREASE BONE STRENGTH |
| 01/24/2002 | WO2002005815A1 Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug |
| 01/24/2002 | WO2002005812A1 Medicaments for chemotherapeutic treatment of disease |
| 01/24/2002 | WO2002005809A1 Dermal for amino laevulinic acid |
| 01/24/2002 | WO2002005794A2 Use of fluorescein derivatives for the treatment of diseases responsive to the activation of the cystic fibrosis transmembrane conductance regulator chloride channel |
| 01/24/2002 | WO2002005792A2 Use of matrix metalloprotease inhibitors for the treatment of cancer |
| 01/24/2002 | WO2002005791A2 Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor |
| 01/24/2002 | WO2002005786A1 Pharmaceutical composition improved in peroral absorbability |
| 01/24/2002 | WO2001070767A3 Therapeutic anti-melanoma compounds |
| 01/24/2002 | WO2001064750A3 Modulation of the activity of the endothelial cel surface receptor ecrtp/dep-1 in the regulation of angiogenesis |
| 01/24/2002 | WO2001062239A3 Novel compositions and uses of dictyostatin compounds |
| 01/24/2002 | WO2001060814A3 Pyrrole substituted 2-indolinone protein kinase inhibitors |
| 01/24/2002 | WO2001060412A3 Modification of biopolymers for improved drug delivery |
| 01/24/2002 | WO2001059115A3 83p5g4: a tissue specific protein highly expressed in prostate cancer |
| 01/24/2002 | WO2001059073A3 Cytotoxic t lymphocytes activated by dendritic cell hybrids |
| 01/24/2002 | WO2001053268B1 Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation |
| 01/24/2002 | WO2001052892A3 Jak/stat pathway inhibitors and the uses thereof |
| 01/24/2002 | WO2001051515A3 Genes differentially expressed in breast cancer |
| 01/24/2002 | WO2001046258A3 Transporters and ion channels |
| 01/24/2002 | WO2001038305A3 Novel il-8 receptor antagonists |
| 01/24/2002 | WO2001036977A8 Identification of disease markers involving mass-based-separation |
| 01/24/2002 | WO2001036470A3 Methods and compositions for detection and treatment of breast cancer, based on breast cancer-associated polypeptides |
| 01/24/2002 | WO2001036005A3 Targeted delivery of therapeutic and diagnostic moieties |
| 01/24/2002 | WO2001034768A3 15 human secreted proteins |
| 01/24/2002 | WO2001032910A3 27 human secreted proteins |
| 01/24/2002 | WO2001025436A3 Endozepine-like polypeptides and polynucleotides encoding same |
| 01/24/2002 | WO2001025397A3 Compositions and methods for tumor-targeted delivery of effector molecules |
| 01/24/2002 | WO2001023357A3 Fused cycloheptane and fused azacycloheptane compounds and their use as integrin receptor antagonists |
| 01/24/2002 | WO2001019860A3 Proteins associated with cell differentiation |
| 01/24/2002 | WO2001014405A3 Methods of obtaining 2-methoxyestradiol of high purity |
| 01/24/2002 | WO2001012819A3 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 01/24/2002 | WO2001008708A3 Enhanced delivery via serpin enzyme complex receptor ligands |
| 01/24/2002 | WO2001000655A3 Therapeutic peptides derived from subsequences of bpi |
| 01/24/2002 | WO2000073478A9 Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration |